Kelley Drye & Warren LLP is an AmLaw 200, Chambers ranked, full-service law firm of more than 350 attorneys and other professionals. For more than 180 years, Kelley Drye has provided legal counsel carefully connected to our client’s business strategies and has measured success by the real value we create.
The FDA has launched a major enforcement initiative against companies marketing unapproved GLP-1 weight loss drug alternatives as "research use only" or "not for human consumption" while simultaneously providing dosing instructions and testimonials. This episode examines how regulators are looking beyond legal disclaimers to focus on actual marketing practices and intended use, signaling heightened scrutiny of the booming market for compounded and unapproved GLP-1 products.
United StatesFood, Drugs, Healthcare, Life Sciences
Donnelly McDowell’s articles from Kelley Drye & Warren LLP are most popular:
within Food, Drugs, Healthcare and Life Sciences topic(s)
in European Union
in European Union
in European Union
in European Union
in European Union
in European Union
in European Union
Kelley Drye & Warren LLP are most popular:
within Antitrust/Competition Law topic(s)
In this episode, we unpack the FDA’s latest enforcement wave targeting GLP-1 “dupes,” where companies have been marketing unapproved injectable products as “research use only” or “not for human consumption,” while simultaneously providing dosing instructions, testimonials, and other signals of intended human use. The FDA’s message is increasingly clear: it will look beyond disclaimers and focus on how products are actually marketed and used, treating misleading labeling as a potential violation of drug laws and a serious public health risk as scrutiny of compounded and unapproved GLP-1 products continues to intensify.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
